zPREDICTA
YC S15 · Acquired · Patient-derived 3D tissue reconstruction models for preclinical…
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
 Known MedicineShared: cell culture, clinical, tumorAcquiredAI | AI | Acquired | YCS20 |
 OriginShared: patient derived, cell, drugActiveAI | AI | Active | YCW26 |
 Verge GenomicsShared: human tissue, patient, drugActiveAI | AI | Active | YCS15 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
 VolumetricShared: human tissue, efficacy, patientAcquiredOther | Other | Acquired | YCW20 |
 Pandorum TechnologiesShared: human tissueNot statedOther | Other | Not stated | 500 Global2018 |
 NovelcareShared: clinical, patient, studyActiveAI | AI | Active | YCW23 |
 Kyo DiagnosticsShared: patient derived, tissue, cultureNot statedOther | Other | Not stated | Plug and Play |
 Rosebud BiosciencesShared: organ, patient, drugActiveAI | AI | Active | YCW22 |
Also from S15 in AI
All of S15
About zPREDICTA
zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.
- YC batch
- S15 · Summer 2015
- Status, per YC
- Acquired
- Category
- AI
- Team size
- 2
- Location
- San Francisco, CA, USA; San Jose, CA, USA
- Checked
- 32m ago
zPREDICTA: questions
Which YC batch was zPREDICTA in?
zPREDICTA was in Y Combinator's Summer 2015 batch (S15).
Is zPREDICTA still active?
Y Combinator lists zPREDICTA as acquired.
Where is zPREDICTA based?
zPREDICTA lists San Francisco, CA, USA; San Jose, CA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.